Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sirolimus-Coated Balloon (SeQuent SCB) Versus Paclitaxel-Coated Balloon (RESTORE DEB) for Recurrent Coronary In-Stent Restenosis Following Prior Paclitaxel-Coated Balloon Therapy: A Multicenter, Randomized, Open-Label, Noninferiority Trial

NCT07920055 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.

NCT NCT07920055 Not yet recruiting Not applicable 106 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07920055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, 106 participants (estimated). Lead sponsor Sir Run Run Shaw Hospital; China. Primary measure: In-Segment Late Lumen Loss at 9 Months.

How it compares

1,721 similar trials: same condition (Coronary Artery Disease) and phase

Enrollment

This trial
106
Middle half
50 to 413
Median
126
Trials with a value
1,716

Months from start to completion

This trial
25
Middle half
17 to 58
Median
32.1
Trials with a value
1,695

Sites

This trial
1
Middle half
1 to 2
Median
1
Trials with a value
1,570
Posted results or a linked paper 51% 881 of 1,721 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Sirolimus-Coated Balloon (SeQuent SCB) Versus Paclitaxel-Coated Balloon (RESTORE DEB) for Recurrent Coronary In-Stent Restenosis Following Prior Paclitaxel-Coated Balloon Therapy: A Multicenter, Randomized, Open-Label, Noninferiority Trial
Lead sponsor
Sir Run Run Shaw Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
November 30, 2028
Enrollment
106 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Coronary Artery Disease

Registry terms: coronary in-stent restenosis

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Sir Run Run Shaw Hospital

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
SeQuent SCB Sirolimus-Coated Balloon Experimental SeQuent SCB sirolimus-coated balloon
Show registry wording

Treatment of eligible recurrent coronary in-stent restenosis with SeQuent SCB sirolimus-coated balloon angioplasty. Up to two balloons may be used per participant under the protocol. All participants receive protocol-directed antiplatelet treatment

RESTORE DEB Paclitaxel-Coated Balloon Active comparator RESTORE DEB paclitaxel-coated balloon
Show registry wording

Treatment of eligible recurrent coronary in-stent restenosis with RESTORE DEB paclitaxel-coated balloon angioplasty. Up to two balloons may be used per participant under the protocol. All participants receive protocol-directed antiplatelet treatment

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
In-Segment Late Lumen Loss at 9 Months Immediately after index procedure and at 9 months
Show registry wording

Difference, in millimeters, between the in-segment minimum lumen diameter immediately after balloon angioplasty and the minimum lumen diameter in the same segment at 9 months, measured by blinded quantitative coronary angiography. The prespecified noninferiority margin for the adjusted mean difference (SeQuent SCB minus RESTORE DEB) is 0.25 mm.

Lead sponsor's other trials

Sir Run Run Shaw Hospital, most recent start first.

Similar trials

Same condition (Coronary Artery Disease) and phase, most recent start first.